A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Efatutazone (Primary) ; Paclitaxel
- Indications Thyroid cancer
- Focus Therapeutic Use
- 20 Jun 2017 Status changed from recruiting to suspended in the Scheduled Interim Monitoring.
- 14 Nov 2016 Planned number of patients changed from 50 to 20.
- 28 Oct 2016 Status changed from suspended to recruiting.